Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$22.17M, compared with $32.94M a year earlier. Trailing-twelve-month net change in cash was $55.02M.
Context
- Net change in cash amounted to 840.2% of revenue in FY2025, up 108.8 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$22.17M or moves back toward the trailing-twelve-month quarterly average of $13.76M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 110.13M USD
- Year-over-year change
- +49.2%
- 4-year CAGR
- +2.0%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 110.13M | +49.2% |
| FY2024 | 2024-12-31 | 73.83M | +178.0% |
| FY2023 | 2023-12-31 | (94.62M) | -61.9% |
| FY2022 | 2022-12-31 | (58.43M) | -157.5% |
| FY2021 | 2021-12-31 | 101.59M | — |
Net Change in Cash vs competitors
How TNXP compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -55.9% is the 5th highest of 10, against a peer median of -87.2%.
- Net change in cash amounts to 313.4% of revenue for TNXP, versus a peer median of 1470.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $100M USD | -769.9% | +42.0% | 169491.5% | |
| LTM Mar 2026 | $55.02M USD | -55.9% | — | 313.4% | |
| FY2025 | €30.44M EUR | +623.1% | +15.9% | 1092.1% | |
| LTM Mar 2026 | $29.02M USD | -44.3% | — | 2529.6% | |
| LTM Mar 2026 | $26.23M USD | -25.0% | — | 1470.4% | |
| LTM Mar 2026 | $25.24M USD | -87.2% | — | — | |
| LTM Mar 2026 | $12.37M USD | -19.8% | — | — | |
| LTM Mar 2026 | $5.53M USD | -92.8% | — | 87.5% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $4.08M USD | -162.5% | -47.7% | — |
| LTM Mar 2026 | $2.34M USD | -182.5% | — | — | |
| Peer median (excluding TNXP) | — | -87.2% | +15.9% | 1470.4% | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Depreciation & Amortization | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.9M | 10.91M | 9.28M | 4.78M | 6.02M |
| Change in Working Capital | 5.78M | (2K) | (35K) | 5.78M | 8.55M |
| Accounts Receivables | 0 | 0 | 0 | (3.68M) | (2.62M) |
| Inventory | 0 | 0 | 61K | 3.74M | 1.73M |
| Accounts Payables | 3.53M | (1.05M) | (3.49M) | 927K | 2.99M |
| Other Working Capital | 2.26M | 1.04M | 3.39M | 4.79M | 6.44M |
| Other Non-Cash Items | 3M | 10.91M | 1.12M | 55.14M | 7.69M |
| Operating Cash Flow | (75.56M) | (98.05M) | (102M) | (60.93M) | (99.84M) |
| Capital Expenditures | (35.31M) | (48.15M) | (7.9M) | (120K) | (3.37M) |
| Acquisitions (Net) | 0 | 0 | (22.17M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 999K | 0 | (1.16M) |
| Investing Cash Flow | (35.31M) | (48.15M) | (29.07M) | (120K) | (4.53M) |
| Debt Repayment | 0 | 0 | 8.94M | (2.35M) | (9.65M) |
| Common Stock Issued | 212.39M | 94.46M | 18.94M | 140.2M | 237.94M |
| Common Stock Repurchased | 0 | 0 | (13.97M) | 0 | (13.76M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 98K | 40K | 22.6M | (2.97M) | 0 |
| Financing Cash Flow | 212.49M | 87.84M | 36.52M | 134.87M | 214.53M |
| Effect of Forex Changes | (31K) | (74K) | (65K) | 4K | (31K) |
| Net Change in Cash | 101.59M | (58.43M) | (94.62M) | 73.83M | 110.13M |
| Free Cash Flow | (110.86M) | (146.2M) | (109.9M) | (61.05M) | (103.21M) |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.